
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis Transcript
Seeking Alpha
公開日時: Jul 27, 2026, 12:30 PM GMT+9
Sentiment Analysis
Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis July 26, 2026 9:00 PM EDT Botanix Pharmaceuticals Limited (BXPHF) is a commercial stage dermatology company operating in Australia and the United States with this FDA-approved product Sofdra, which is available in America. Sofdra is a prescription-only topical gel medicine, which used to treat excessive underarm sweating or more formally known as primary axillary hyperhidrosis. It is used in treating adults and children aged 9 and over. The company has transitioned from a development stage business into a revenue-generating commercial entity with Sofdra as its primary growth driver.
Source: Seeking Alpha
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。